Neurokinin receptor antagonists
by
Stahl SM
Leroy V, Mauser P, Gao Z, Peet NP
Aventis Pharmaceuticals,
Route 202-206,
Bridgewater, NJ 08807, USA.
Expert Opin Investig Drugs 2000 Apr; 9(4):735-746


ABSTRACT

Studies on tachykinin peptides and the corresponding neurokinin receptors (NKr) have increased dramatically recently due to the discovery of selective, orally-active, metabolically stable and sometimes CNS penetrating NKr antagonists. After demonstrating the potential use for NKr antagonists in animal models, some compounds have recently progressed into clinical trials and a few results have been published. NKr antagonists have demonstrated efficacy for the treatment of emesis and depression, while results in other areas have been disappointing. Nonetheless, this area is coming to the exciting time of proof of concept in humans. Demonstration of the involvement of tachykinin peptides in biological functions continues to grow, as do the potential indications for NKr antagonists. More drug candidates are undergoing clinical trials for various conditions and these results could widen the potential use for NKr antagonists.

SPAs
Options
Aprepitant
Substance P
SSRIs/SNRIs
21st century
Neurotrophins
Sigma ligands
New antidepressants
Substance P and opiates
Substance P antagonists
Neurokinins and Substance P
Neurokinin receptor-1 antagonists
Substance P and major depression
Substance P: effects on sleep, mood, and neuroendocrine function

Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family